Mizuho raised the firm’s price target on Immunocore (IMCR) to $38 from $37 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore announces R&D chief resignation and leadership reshuffle
- Immunocore announces EVP, Research, Development Berman to depart
- Immunocore Sets 2026 Strategic Priorities for Melanoma Growth
- Immunocore announces 2026 strategic priorities
- Immunocore price target raised to $40 from $36 at Morgan Stanley